Profile data is unavailable for this security.
About the company
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
- Revenue in USD (TTM)0.00
- Net income in USD-82.59m
- Incorporated2017
- Employees55.00
- LocationCelcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
- Phone+1 (763) 392-0767
- Fax+1 (302) 655-5049
- Websitehttps://www.celcuity.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contineum Therapeutics Inc | -100.00bn | -100.00bn | 510.35m | 31.00 | -- | 2.35 | -- | -- | -- | -- | -- | 8.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| OmniAB Inc | 21.71m | -62.38m | 522.28m | 106.00 | -- | 1.78 | -- | 24.05 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Neurogene Inc | 925.00k | -55.44m | 529.49m | 91.00 | -- | 3.41 | -- | 572.42 | -4.93 | -4.93 | 0.0748 | 11.93 | 0.0068 | -- | -- | 10,164.83 | -40.49 | -32.70 | -43.33 | -34.73 | -- | -- | -5,993.62 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| ACELYRIN Inc | 0.00 | -299.80m | 537.97m | 130.00 | -- | 0.9445 | -- | -- | -3.06 | -3.06 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -40.33 | -- | -43.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Entrada Therapeutics Inc | 239.40m | 104.44m | 546.09m | 168.00 | 4.96 | 1.27 | 5.06 | 2.28 | 2.96 | 2.96 | 6.92 | 11.57 | 0.445 | -- | 41.93 | 1,505,642.00 | 19.41 | -- | 24.17 | -- | -- | -- | 43.63 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Celcuity Inc | 0.00 | -82.59m | 549.90m | 55.00 | -- | 3.11 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Foghorn Therapeutics Inc. | 35.19m | -86.45m | 552.73m | 116.00 | -- | -- | -- | 15.71 | -1.95 | -1.95 | 0.7895 | -0.2589 | 0.1053 | -- | -- | 303,319.00 | -25.88 | -31.35 | -30.84 | -35.69 | -- | -- | -245.69 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Altimmune Inc | 409.00k | -101.35m | 553.64m | 59.00 | -- | 3.63 | -- | 1,353.65 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 557.34m | 180.00 | -- | 2.16 | -- | 3.40 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Alector Inc | 55.28m | -160.66m | 559.60m | 245.00 | -- | 3.72 | -- | 10.12 | -1.81 | -1.81 | 0.6162 | 1.55 | 0.0864 | -- | -- | 226,536.90 | -25.11 | -20.00 | -32.15 | -23.81 | -- | -- | -290.66 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Eliem Therapeutics Inc | 0.00 | -64.20m | 565.32m | 9.00 | -- | 2.53 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Regenxbio Inc | 89.04m | -241.08m | 577.76m | 344.00 | -- | 1.66 | -- | 6.49 | -5.27 | -5.27 | 1.93 | 7.06 | 0.1423 | -- | 4.03 | 258,848.80 | -38.52 | -16.75 | -46.55 | -19.08 | 56.78 | 78.27 | -270.74 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| SS Innovations International Inc | 14.41m | -23.68m | 580.51m | 239.00 | -- | 34.18 | -- | 40.29 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 582.30m | 28.00 | -- | 2.01 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Allogene Therapeutics Inc | 65.00k | -279.42m | 585.51m | 232.00 | -- | 1.14 | -- | 9,007.88 | -1.59 | -1.59 | 0.0004 | 2.46 | 0.00009 | -- | -- | 280.17 | -39.41 | -28.46 | -42.15 | -30.21 | -- | -- | -429,881.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Data as of Sep 20 2024. Currency figures normalised to Celcuity Inc's reporting currency: US Dollar USD
50.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Jun 2024 | 3.47m | 9.36% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.76m | 7.45% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 2.36m | 6.38% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 1.87m | 5.06% |
| Eventide Asset Management LLCas of 30 Jun 2024 | 1.54m | 4.15% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.52m | 4.10% |
| Commodore Capital LPas of 30 Jun 2024 | 1.46m | 3.95% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.34m | 3.61% |
| Samlyn Capital LLCas of 30 Jun 2024 | 1.33m | 3.58% |
| Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 1.21m | 3.27% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
